LentiGlobin gene therapy: Phase I/II data

bluebird bio (formerly Genetix Pharmaceuticals Inc.) and colleagues reported data from the first patient treated with its LentiGlobin gene therapy in an ongoing Phase I/II trial. At 33 months post-ge...